Clinical Trials Directory

Trials / Completed

CompletedNCT01579539

The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Medical University of Vienna · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Thyroid-associated ophthalmopathy (TAO), also called Graves' ophthalmopathy or thyroid eye disease, is a common orbital disease in adults. Patients with TAO, especially in its active phase, often complain about symptoms of ocular surface discomfort, including excess tearing, gritty sensation, increased sensitivity to light and foreign-body sensation, which are similar to inflammatory ocular surface disorders such as dry-eye syndrome (DES). Incomplete blink, increased proptosis and greater palpebral fissure width in TAO accelerates tear evaporation, which increases the tear fluid's osmolarity, and results in ocular surface damage. The administration of intravenous glucocorticoids can be an effective treatment for TAO. The rationale of the present study is to assess the effect of intravenously administered glucocorticoids on the signs of DES in patients with TAO with new methods such as measurement of tear film thickness, tear film osmolarity and scattering of the tear film and well established methods for assessment of the severity of DES. Additionally, impression cytology and determination of tear cytokines/chemokines will be performed to obtain information about inflammatory processes on the ocular surface.

Conditions

Interventions

TypeNameDescription
DRUGMethylprednisolone500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
DRUGEsomeprazole40mg i.v. infusion once a week for 12 weeks

Timeline

Start date
2013-06-27
Primary completion
2017-05-18
Completion
2017-05-18
First posted
2012-04-18
Last updated
2020-02-20

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT01579539. Inclusion in this directory is not an endorsement.